Dan Zabrowski, Head of Roche's Applied Science, together with a delegation of executives of this company, met on Friday 28th September with VHIR's director and members of the research group in liver diseases at the facilities of the institute. The meeting served to emphasize in the relations already established between ROCHE and VHIR, with good results and the collaboration in different projects. One of them, probably the most important is called 'Study of quasispecies of hepatitis viruses B and C (HBV and HCV) and genomic polymorphisms associated with response to antiviral therapy by pyrosequencing', but also other strategies of present and immediate future that are studied on both parts.From Roche also were in the meeting Erik Hawkinson, Head of Strategic Marketing-Applied Science, Carlos Freixas, Director Applied Science Spain, Artur Palet, Director Business Development Spain and Miguel Álvarez, Senior Project Manager Applied Science Spain. From VHIR, besides its director, Dr. Joan Comella, participated, as members of the research team on liver diseases, Dr. Juan Ignacio Esteban Mur, Head of Hepatitis C virus (HCV) Research. Liver Unit, Dr. Josep Quer, Responsible of Molecular Biology and Cell Culture on HCV Research. Liver Unit, and Dr. Josep Gregori, from biotechnician from the liver diseases group. In addition, also were in the meeting from VHIR Dr. Fátima Núñez, Director Technical & Scientific Support Area, and Raquel Egea, head of innovation.At the end of the meeting there was a visit to the liver diseases lab and VHIR's corelabs.